LFKRI is the research branch of New York Blood Center. Since its establishment in 1964, LFKRI's research efforts have paved the way for new blood-related products, techniques and therapies and has resulted in numerous landmark patents and licenses.
LFKRI continues to be at the forefront of blood disease research
Scientists at LFKRI have identified a subset of white blood cells which can remove the sickle blood cells attached to the cells of the vessel wall.
Dr. Asim Debnath’s laboratory at the New York Blood Center has been devoted to discovering novel drugs against HIV.
Previously it was unknown how formed platelets in the circulation maintain a low basal activati...
This manufacturing and collaboration agreement covers the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001.
Zika virus remains a threat to public health due to its close association with microcephaly and other severe birth defects.
MERS-CoV, a newly emerging, highly pathogenic infectious virus, continues to threat public health worldwide with high mortality rate (about 35%).
We offer a comprehensive menu of services and products to support and manage the full spectrum of transfusion medicine, regenerative medicine and cellular-therapy related research projects, from basic science to full scale clinical trials.
New York Blood Center Enterprises (NYBCe) is one of the largest independent, community-based, nonprofit blood centers in the United States.